Opaleye Management Continues Patient Buying Surge, Adds 775 Shares to 16.4% Stake in SOL‑GEL Technologies Amid 800% Stock Rally

Opaleye Management’s Latest Stake‑Build at SOL‑GEL Technologies

The most recent insider transaction on July 13, 2026, shows Opaleye Management Inc. purchasing an additional 775 ordinary shares of SOL‑GEL Technologies for an average price of $73.89 per share. While the transaction size is modest—just under 0.3 % of the company’s outstanding shares—it is part of a steady buying cadence that has already seen the fund’s stake rise from roughly 15 % in early 2025 to 16.4 % as of mid‑July. The incremental purchase comes at a market price of $75.39, a 3.3 % week‑to‑week gain, and reflects a broader confidence in the company’s pipeline, especially its flagship topical dermatological therapies.

Implications for Investors and the Company’s Outlook

Investors should view Opaleye’s activity as a bullish signal. The fund’s cumulative purchases have been priced consistently near the current market price, indicating a willingness to pay for perceived upside rather than just exploiting a low. The transaction volume aligns with SOL‑GEL’s recent earnings momentum—its stock has surged more than 800 % year‑to‑date, driven by positive clinical data and expanding U.S. and European sales channels. A 12‑point social‑media sentiment lift and 14 % buzz intensity around this transaction suggest that the market is noticing and reacting favorably, which could translate into short‑term liquidity and price support. For long‑term investors, the steady accumulation signals that the firm’s management team is likely aligned with the fund’s view that the company’s top‑line growth will continue as it rolls out new dermatology indications.

Opaleye Management: A History of Patient, Persistent Buying

Opaleye’s historic transaction pattern at SOL‑GEL shows a disciplined, patient approach. Starting in December 2025, the fund began buying in increments of 1,000–4,000 shares per filing, steadily building a 15 % stake. The fund’s average purchase price has climbed from $39.50 in December 2025 to $73.69 by July 2026, reflecting both the company’s price appreciation and the fund’s willingness to invest at higher valuations when the business fundamentals support it. Notably, Opaleye has maintained a consistent holding of 15,000 shares (via a managed account) since May 2026, underscoring its commitment to a long‑term position rather than speculative trading.

This buying behavior aligns with Opaleye’s broader investment mandate of acquiring stakes in high‑growth, clinical‑stage pharmaceutical companies. Their pattern—steady accumulation at low price points, followed by disciplined purchases as valuation improves—suggests a strategy focused on capturing upside while managing risk through a diversified portfolio.

What Does This Mean for SOL‑GEL’s Future?

The cumulative buying, combined with the firm’s robust pipeline and expanding market presence, positions SOL‑GEL as a candidate for continued upside. The stock’s negative P/E of –197.46 reflects the early‑stage nature of the business, yet the 4.6 % monthly gain and 818 % yearly climb illustrate significant investor enthusiasm. If the company successfully commercializes its topical dermatological products and secures further regulatory approvals, Opaleye’s confidence could become a catalyst for broader institutional interest, potentially driving the stock higher and expanding liquidity.

Key Takeaway for Investors

Opaleye Management’s recent purchase is a micro‑indication of a larger, patient‑buying strategy that has already built a substantial stake in SOL‑GEL Technologies. For investors, this transaction—coupled with the company’s strong price performance and positive market sentiment—signals that SOL‑GEL is likely to stay in the spotlight of growth‑focused investors. Those seeking exposure to the dermatology drug sector may consider this as a green light to evaluate a long‑term position, while short‑term traders should note the potential for continued upward momentum driven by institutional accumulation.